Lundbeck Buys 4.6% Stake in Biotie

On Friday, Lundbeck announced that they are investing 10 million euros to buy a stake in Biotie Therapies Corp, Lundbeck’s partner on the investigational alcohol dependence drug Selincro. The investment signifies 4.6% of Biotie’s total equity capital, and a 25% premium to the Finnish biotech’s share price on September 6.  In association with the agreement,

Continue Reading